⚡ Emergency Recognition & Management
1
Subarachnoid Hemorrhage: Sudden severe headache, nuchal rigidity → Immediate CT/CTA
2
Cyst Infection: Fever + flank pain in ADPKD → Fluoroquinolones (ciprofloxacin/levofloxacin) 4-6 weeks duration
3
Cyst Hemorrhage: Acute severe flank pain + gross hematuria, stable hemoglobin → Conservative management
4
Cyst Rupture: Sudden severe pain followed by rapid improvement → Usually self-resolves
5
Hypertensive Crisis: BP >180/120 + symptoms → Gradual reduction, avoid rapid drops
🚨 Cyst Complications: Recognition & Management
🩸 Cyst Hemorrhage
- Presentation: Acute severe flank pain + gross hematuria
- Key Feature: Hemoglobin usually stable (bleeding into cyst)
- Management: Conservative, usually self-limited
- Duration: Hematuria resolves in days to weeks
🦠 Cyst Infection
- Presentation: Fever, flank pain, and elevated WBC
- Best Antibiotics: Fluoroquinolones (excellent cyst penetration)
- Alternatives: Trimethoprim-sulfamethoxazole
- Duration: 4-6 weeks treatment typically needed
- Avoid: Beta-lactams, nitrofurantoin (poor penetration)
💥 Cyst Rupture
- Presentation: Sudden severe pain followed by rapid improvement
- Mechanism: Pressure relief as cyst contents leak
- Hematuria: May have brief episode
- Management: Usually self-resolves without treatment
📊 Clinical Significance
- Global Prevalence: Up to 12 million people worldwide
- ESRD Cause: 4th leading cause of end-stage renal disease
- Most Common: Hereditary kidney disease globally
- Healthcare Burden: Significant economic impact
- Variability: Wide clinical spectrum from mild to severe
- Systemic Disease: Multiple organ involvement
🧬 Genetic Basis
- PKD1 Gene: 78% of cases, chromosome 16p13.3
- PKD2 Gene: 15% of cases, chromosome 4q21-23
- Rare Genes: IFT140, GANAB, ALG5, ALG9, NEK8, DNAJB11
- PKD1 Severity: More severe disease, earlier ESRD onset
- PKD2 Course: Milder phenotype, later progression
- Protein Products: Polycystin-1 and polycystin-2
🔍 Diagnostic Criteria
Ravine Criteria (Age-Dependent)
- 🔹 15-29 years: ≥2 cysts (unilateral or bilateral)
- 🔹 30-59 years: ≥2 cysts in each kidney
- 🔹 ≥60 years: ≥4 cysts in each kidney
Pei Unified Criteria
- ✅ 15-39 years: ≥3 cysts (100% PPV)
- ❌ >40 years: ≤2 cysts excludes ADPKD (100% NPV)
- 🎯 Advantage: Works for PKD1 and PKD2
🧬 Genetic Testing Decision Aid
Genetic Testing Recommendation
Genetic testing recommended
Based on clinical scenario and family history
📈 Mayo Imaging Classification
- Class 1A: Typical imaging, height-adjusted TKV <600 mL/m
- Class 1B: Typical imaging, TKV 600-1,200 mL/m
- Class 1C: Typical imaging, TKV >1,200 mL/m
- Class 1D: Multiple liver cysts, TKV >1,200 mL/m
- Class 1E: Severe polycystic disease
- Predictive Value: Best predictor of future decline
⚖️ Progression Risk Factors
- PKD1 Mutations: More severe disease, average ESRD age 54
- PKD2 Mutations: Milder progression, average ESRD age 74
- Early Hypertension: Before age 35 indicates rapid progression
- Male Gender: More rapid progression than females
- Height-Adjusted TKV: Most important predictor of progression
- Family History: Grandfather's transplant suggests moderate progression
💊 Tolvaptan: First Disease-Modifying Therapy
1
Patient Selection: CKD stages 1-3 (eGFR >25), evidence of rapid progression, adequate liver function
2
Progression Evidence: Declining eGFR, increasing TKV, or high-risk features (height-adjusted TKV >600 mL/m)
3
Critical Monitoring: Monthly liver function tests for first 18 months (ALT >3x ULN requires discontinuation)
4
Safety Profile: Idiosyncratic liver injury in 4.4% of patients - most important monitoring requirement
5
Efficacy Monitoring: Annual TKV by MRI, eGFR decline rate assessment
📏 Height-Adjusted TKV Calculator
Height-Adjusted TKV
277 mL/m
Mayo Class 1A - Low risk
Tolvaptan not indicated
🧠 Intracranial Aneurysm Screening
⚠️ CRITICAL: MRA vs MRI for Aneurysm Screening
MRA (Magnetic Resonance Angiography) is the test of choice for intracranial aneurysm screening, NOT standard brain MRI. MRA specifically images blood vessels and can detect aneurysms ≥3mm. Standard brain MRI does not adequately visualize cerebral vasculature.
Epidemiology
- ADPKD Prevalence: 8-10% (4x higher than general population)
- General Population: 2-3%
- Family History: Higher screening frequency needed
- High-Risk Features: >7mm, irregular shape, symptoms
Screening Protocol
- Test of Choice: MRA brain (not standard MRI)
- Initial: Symptoms or high-risk occupation
- Repeat: Every 5-10 years if negative
- Indications: Headaches, family history, anxiety
High-Priority Screening Candidates
Family history of aneurysms or subarachnoid hemorrhage, high-risk occupations, patient anxiety, new headaches
🫀 Polycystic Liver Disease
- Prevalence: 81.7% of ADPKD patients have hepatic cysts
- Age Correlation: 20% in 3rd decade → 75% in 7th decade
- Gender Difference: Women have larger, more numerous cysts
- Estrogen Effect: Pregnancy and HRT increase cyst growth
- Symptoms: Abdominal pain, early satiety, GERD
- Severe Disease: May require intervention or transplant
🦴 Other Extrarenal Manifestations
- Colonic Diverticulosis: Increased risk vs general population
- Pancreatic Cysts: ~9% of patients >20 years
- Cardiac Valves: Mitral valve prolapse more common
- Thoracic Aortic Aneurysms: Elevated risk reported
- Abdominal Aortic: No increased risk
- Hernia: Inguinal and umbilical hernias common
🏥 Comprehensive ADPKD Management Strategy
1
Blood Pressure Control: ACE-I/ARB first-line, aggressive targets <110/75 mmHg in young patients with preserved function
2
Water Intake: Target 3-4L daily to suppress vasopressin (limited evidence but low risk intervention)
3
Screening Programs: MRA (not MRI) for aneurysms, family screening protocols
4
Disease Monitoring: MRI for TKV measurement (superior to volumetric CT), eGFR tracking
5
Tolvaptan Evaluation: CKD stages 1-3 with rapid progression, monthly LFTs × 18 months
6
Transplant Planning: Refer at eGFR 20-25 mL/min/1.73m², usually unilateral nephrectomy
📷 Best Imaging Modalities for ADPKD
🧲 MRI for Total Kidney Volume
- Superior to CT: More accurate TKV measurements
- No Radiation: Safe for repeated monitoring
- Better Contrast: Superior soft tissue contrast
- Gold Standard: For Tolvaptan eligibility assessment
🧠 MRA for Aneurysm Screening
- Test of Choice: NOT standard brain MRI
- Vessel Imaging: Specifically visualizes cerebral vasculature
- Detection Limit: Can identify aneurysms ≥3mm
- No Contrast: Time-of-flight technique preferred
🔍 Ultrasound for Diagnosis
- Initial Screening: First-line diagnostic tool
- Age-Specific Criteria: Pei-Ravine criteria application
- Limitations: Cannot accurately measure TKV
- Family Screening: Cost-effective for relatives
👨👩👧👦 Family Screening Protocols
Age 15-39 Years
- Diagnostic Threshold: ≥3 cysts (bilateral) indicates ADPKD
- Special Consideration: Ages 15-19, even 1-2 cysts may be significant
- Genetic Testing: Consider for family planning purposes
- Repeat if Negative: Every 3-5 years until age 30
Age 40+ Years
- Exclusion Rule: ≤2 cysts rules out ADPKD (high NPV)
- Diagnostic Threshold: ≥3 cysts per kidney for ages 40-59
- Age 60+: ≥4 cysts per kidney required
- Late Negative: Very unlikely to develop ADPKD after 30
Follow-up Protocols
- Initial Negative (Age 15): Repeat at age 18
- Ages 18-30: Every 3-5 years if negative
- After Age 30: If consistently negative, ADPKD very unlikely
- Genetic Counseling: Important for all family members
🫀 Transplant Planning & Surgical Considerations
⏰ Transplant Timing
- Referral Timing: eGFR approaches 20-25 mL/min/1.73m²
- Early Planning: Allows time for workup and living donor identification
- Current Function: eGFR 78 - too early for formal evaluation
- Patient Education: Appropriate to begin discussions
⚔️ Nephrectomy Considerations
- Usually Unilateral: Single kidney removal to create space
- Bilateral Rare: Carries significant risk of severe hypotension
- Immediate Risk: Bilateral requires immediate transplantation
- Indications: Mass effect, recurrent infections, space constraints
🎯 ADPKD-Specific Factors
- Unique Consideration: Large kidneys may need removal
- Good Outcomes: Similar to other kidney diseases
- Living Donors: Can receive from relatives (if unaffected)
- Space Planning: Surgical approach differs from other causes
🎯 Key Clinical Pearls
Disease Modification
Tolvaptan is first approved therapy that slows kidney function decline in high-risk patients with adequate monitoring.
TKV Predicts Progression
Height-adjusted total kidney volume is the most important predictor of future renal function decline and ESRD.
Systemic Disease
ADPKD affects multiple organs requiring comprehensive screening for intracranial aneurysms and liver involvement.
Genetic Counseling
PKD1 vs PKD2 mutations significantly affect disease severity and progression timeline, informing patient counseling.